We now turn to prevention of VTE in high-risk
patients, and will review three prevention trials that tested tinzaparin
in patients who were undergoing hip or knee replacement. The first trial
randomized patients to tinzaparin at 50 IU/kg body weight given once
daily or to placebo (saline) injections. Injections were given 2 hrs.
before surgery and continued for 7 days. The study was conducted in
a double-blind manner. Baseline data show that the two groups had similar
risk factors at entry.
